Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2016 - 2026)
Supernus Pharmaceuticals has reported Other Non-Current Assets over the past 15 years, most recently at $63.8 million for Q4 2025.
- Quarterly Other Non-Current Assets changed N/A to $63.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $63.8 million for FY2025, N/A changed from the prior year.
- Other Non-Current Assets was $63.8 million for Q4 2025 at Supernus Pharmaceuticals, up from $1.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $63.8 million in Q4 2025 and troughed at $1.4 million in Q3 2025.
- The 5-year median for Other Non-Current Assets is $39.8 million (2022), against an average of $38.3 million.
- Year-over-year, Other Non-Current Assets skyrocketed 5523.98% in 2021 and then fell 23.83% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $49.2 million in 2021, then fell by 19.15% to $39.8 million in 2022, then dropped by 2.47% to $38.8 million in 2023, then decreased by 7.55% to $35.9 million in 2024, then soared by 77.75% to $63.8 million in 2025.
- Per Business Quant, the three most recent readings for SUPN's Other Non-Current Assets are $63.8 million (Q4 2025), $1.4 million (Q3 2025), and $28.0 million (Q2 2025).